Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients

Dermatology

Volumn 214, Issue 1, 2006, Pages 8-14

  Weinlich, Georg ^a   Murr, Christian ^a   Richardsen, Laura ^a   Winkler, Christiana ^a   Fuchs, Dietmar ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Melanoma, prognostic factor; Neopterin; Tryptophan

Indexed keywords

KYNURENINE; NEOPTERIN; TRYPTOPHAN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER PATIENT; CANCER SURVIVAL; CANCER SURVIVOR; CAUSE OF DEATH; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NEOPTERIN; PROGNOSIS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE; TRYPTOPHAN; TUMOR MARKERS, BIOLOGICAL;

EID: 33845920042     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096906     Document Type: Article

References (32)

1. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000;100:57-70.
2. Mapara MY, Sykes M: Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 2004;22:1136-1151.
3. Schroder K, Hertzog PJ, Ravasi T, Hume DA: Interferon-γ: an overview of signals, mechanisms and functions. J Leukoc Biol 2004;75:163-189.
4. Brandacher G, Schroecksnadel K, Winkler C, Margereiter R, Fuchs D: Antitumoral activity of interferon-γ involved in impaired immune function in cancer patients. Curr Drug Metabol 2006;7:599-612.
5. Taylor MW, Feng GS: Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J 1991;5:2516-2522.
6. Pfefferkorn ER: Interferon gamma blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan. Proc Natl Acad Sci USA 1984;81:908-992.
7. Mellor AL, Munn DH: Tryptophan catabolism and regulation of adaptive immunity. J Immunol 2003;170:5809-5813.
8. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 2003;9:1269-1274.
9. Hwu P, Du MX, Lapointe R, Do M, Taylor MW, Young HA: Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J Immunol 2000;164:3596-3599.
10. Munn DH: Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol 2006;18:220-225.
11. Lee JH, Torisu-Itakara H, Cochran AJ, Kadison A, Huynh Y, Morton DL, Essner R: Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res 2005;11:107-112.
12. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, Candeloro P, Belladonna ML, Bianchi R, Fioretti MC, Puccetti P: CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002;3:1097-1101.
13. Laich A, Neurauter G, Widner B, Fuchs D: More rapid method for simultaneous measurement of tryptophan and kynurenine by HPLC. Clin Chem 2002;48:579-581.
14. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, Reibnegger G, Swetly P, Troppmair J, Wachter H: Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med 1984;160:310-316.
15. Werner ER, Bitterlich G, Fuchs D, Hausen A, Reibnegger G, Szabo G, Dierich MP, Wachter H: Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci 1987;41:273-280.
16. Wirleitner B, Reider D, Ebner S, Böck G, Widner B, Jaeger M, Schennach H, Romani N, Fuchs D: Monocyte-derived dendritic cells release neopterin. J Leukocyte Biol 2002;72:1148-1153.
17. Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG: Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS. Adv Exp Med Biol 1991;294:425-435.
18. Murr C, Berchtold J, Norer B, Waldhart E, Wachter H, Fuchs D: Neopterin is a prognostic parameter in patients with squamous-cell carcinomas of the oral cavity. Int J Cancer 1998;79:476-480.
19. Wirleitner B, Neurauter G, Schrocksnadel K, Frick B, Fuchs D: Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem 2003;10:1581-1591.
20. Schroecksnadel K, Winkler C, Fuith LC, Fuchs D: Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Lett 2005;223:323-329.
21. Huang A, Fuchs D, Widner B, Glover C, Henderson DC, Allen-Mersh TG: Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer 2002;86:1691-1696.
22. Kim CJ, Reintgen DS, Balch CM; AJCC Melanoma Staging Committee: The new melanoma staging system. Cancer Control 2002;9:9-15.
23. Fuchs D, Weiss G, Reibnegger G, Wachter H: The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious and malignant diseases. Crit Rev Clin Lab Sci 1992;29:307-341.
24. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
25. Schroecksnadel K, Wirleitner B, Winkler C, Fuchs D: Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 2006;364:82-90.
26. Munn DH, Mellor AL: IDO and tolerance to tumors. Trends Mol Med 2004;10:15-18.
27. Denz H, Fuchs D, Huber H, Nachbaur D, Reibnegger G, Thaler J, Werner ER, Wachter H: Correlation between neopterin, interferon-gamma and haemoglobin in patients with haematological disorders. Eur J Haematol 1990;44:186-189.
28. Reibnegger G, Hetzel H, Fuchs D, Fuith LC, Hausen A, Werner ER, Wachter H: Clinical significance of neopterin for prognosis and follow-up in ovarian cancer. Cancer Res 1987:47:4977-4981.
29. Giusti RM, Maloney EM, Hanchard B, Morgan OSC, Steinberg SM, Wachter H, Williams E, Cranston B, Fuchs D, Manns A: Differential patterns of serum biomarkers of immune activation in human T-cell lymphotropic virus type I-associated myelopathy/ tropical spastic pararesis and adult T-cell leukemia/lymphoma. Cancer Epidemiol Biomarkers Prevent 1996;5:699-709.
30. Wolf AM, Wolf D, Rumpold H, Moschen AR, Kaser A, Obrist P, Fuchs D, Brandacher G, Winkler C, Geboes K, Rutgeerts P, Tilg H: Overexpression of indoleamine 2,3-dioxygenase (IDO) in human inflammatory bowel disease. Clin Immunol 2004;113:47-55.
31. Weiss G, Kronberger P, Conrad F, Bodner E, Wachter H, Reibnegger G: Neopterin and prognosis in patients with adenocarcinoma of the colon. Cancer Res 1993;53:260-265.
32. Gajewski TF: Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res 2006;12:2326s-2330s.